3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Myelodysplastic Syndromes
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Leukemia, Myeloid, Acute
9
Leukemia
9
Hematologic Neoplasms
7
Lymphoma, Non-Hodgkin
6
Lymphoma
5
Primary Immunodeficiency Diseases
3
Multiple Myeloma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Cytopenia
3
Anemia, Aplastic
3
Thalassemia
2
Osteopetrosis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hodgkin Disease
2
Hemoglobinopathies
2
Fanconi Anemia
2
Anemia, Sickle Cell
2
Anemia, Diamond-Blackfan
2
Anemia
2
Uveal Melanoma
1
Recurrence
1
Neoplasms, Plasma Cell
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Lymphoproliferative Disorders
1
Interventions
fludarabine
6
Tacrolimus
6
Busulfan
6
blinatumomab
5
Rituximab
5
Cyclophosphamide
5
fludarabine phosphate
4
Peripheral Blood Stem Cell Transplantation
4
Mycophenolic Acid
4
Epoetin Alfa
4
venetoclax
3
Whole-Body Irradiation
3
Methotrexate
3
Darbepoetin alfa
3
Alemtuzumab
3
ponatinib
2
ibrutinib
2
entrectinib
2
alectinib
2
Thiotepa
2
Therapeutics
2
Patient Reported Outcome Measures
2
Mesna
2
Melphalan
2
Everolimus
2
Early Intervention, Educational
2
Bone Marrow Transplantation
2
Antilymphocyte Serum
2
vandetanib
1
trametinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
AP 1903 reagent
×
Other hematologic neoplasm
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled